Biotyscience Inc
E-mail biotyscience@gmail.com
info@biotyscience.com
Tel 400-669-8850
Cat No | ADMD-091 |
Conjugate | |
Type | 重组蛋白 |
Source | HEK293 |
Tag | Fc |
Size | 1mg |
Application | Immunology |
Format | Liquid |
Purity | >95 %, SDS-PAGE |
Concentration | Please refer to the vial lable for the specific concentration. |
Buffer | Supplied in PBS |
Species | Human |
Storage | Store at -20 degree. Avoid repeated freeze/thaw cycles. |
Synonyms | FLT4, FLT-4, FLT41, LMPH1A, PCL, VEGFR3, VEGFR-3 |
Purification | Protein A/G |
Note | For research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. |
MolecularWeight | 110.5 kDa |
Description | |
Background | FLT4 (Fms-related tyrosine kinase 4; also known as VEGFR3) is the main receptor for VEGFC (vascular endothelial growth factor C), and its activation mediates LEC (lymphatic endothelial cell) proliferation, migration, and surviva. FLT4 and the ligand VEGFC increase their expression in macrophages upon bacterial infection. Studies have demonstrated the critical roles of the FLT4-mediated pathway in the regulation of lymphatic and blood vascular development. FLT4 and its ligand VEGFC are expressed in leukemic blasts in AML and that the role of this signaling axis is closely related to blast survival. In addition, VEGFC and FLT4 are expressed in the BM (bone marrow) of AML (Acute myeloid leukemia) and VEGFC can protect AML blasts against chemotherapy by inducing their proliferation, showing the importance of VEGFC signaling in blast maintenance. |